Video Library

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Emerging Molecular Targets For Advanced Non-Small Cell Lung Cancer (NSCLC)

We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this video, Dr. Ramy Sedhom introduces us to Dr. Elizabeth Kessler, from the University of Coloradeo Cancer Center. For more information on Dr. Kessler, please visit her bio here. In part one of

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.

Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

GRACE sat down with Dr. Marco Ruiz to discuss information regarding acute myeloid leukemia (AML) in elderly patients (Leucemia aguda mieloide (LMA) en la población de tercera edad). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

GRACE sat down with Dr. Marco Ruiz to discuss information regarding when and who to refer for hematopoietic cell transplantation (HCT) (¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?). Stay tuned for more on our continuing video series with our Spanish speaking

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of fms related tyrosine kinase 3 (flt3) and myeloproliferative neoplasms (MPN) mutations in acute myeloid leukemia (AML) (¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias

For our 16th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss ALK rearrangements, what they are who has them.

For our 17th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss first line therapy for NSCLC patients that have anaplastic lymphoma kinase (ALK) positive.

For our 18th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss acquired resistance to targeted therapies: biology and different clinical patterns.

For our 19th video in the GRACE Spanish Lung Cancer Library, Dr. Brian Hunis, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers. In this video Dr. Hunis discusses second line therapy for NSCLC patients who are ALK positive.

Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses liquid biopsies for EGFR T790 non-small cell lung cancer (NSCLC). We would like to thank the following companies for their support of this program